Approval · Notice of Compliance 7930 · 2006
SUPREFACT: Notice of Compliance 7930
Issued May 4, 2006
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 7930
- Date
- May 4, 2006
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Luteinizing hormone-releasing hormone (lh-rh) analogue
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SUPREFACT | 02225166 | Marketed |
| SUPREFACT | 02225158 | Cancelled Post Market |
| SUPREFACT DEPOT (2 MONTHS) | 02228955 | Dormant |
| SUPREFACT DEPOT (3 MONTHS) | 02240749 | Dormant |
Medicinal ingredients
- BUSERELIN ACETATE 1 MG per ML
- BUSERELIN ACETATE 6.3 MG per IMP
- BUSERELIN ACETATE 9.45 MG per IMP